Linked Life Data

18070712

Source:http://linkedlifedata.com/resource/pubmed/id/18070712

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-12-11
pubmed:abstractText
Multiple myeloma must be distinguished from monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and several other closely related plasma-cell disorders. In recent years, new systems have emerged for diagnosis, staging, and risk stratification of myeloma. The criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System (ISS) is the standard for staging of myeloma. However, for therapeutic purposes, a risk-stratification model is used to define high-risk patients who can benefit from novel therapeutic strategies. The International Myeloma Working Group uniform response criteria have been developed as the standard for response assessment in current and future clinical trials. The criteria incorporate the category 'very good partial response' (VGPR) which, given its importance in predicting outcome following therapy, should be reported in all trials; such reporting will also enable better comparisons between therapies.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1521-6926
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
665-80
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
pubmed:affiliation
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural